Lead Product(s): Odevixibat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status: Phase III Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2020
The PEDFIC 1 trial is studying both high and low dose odevixibat in both PFIC type 1 and type 2 patients who are 6 months to 18 years of age.